Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Overview
3. Why are new therapeutic approaches important
4. Prevention and screening
5. Current cancer therapy: non-surgical
6. Most chemotherapy targets DNA
7. Chemotherapy effects
8. Current state of cancer therapy: Efficacy
9. Current state of cancer therapy: Toxicity
10. Molecular pathogenesis of cancer
11. Pursuing targeted therapy in cancers
12. Targeted biologic therapies
13. Potential targets in cancer
14. Evolving targets and agents
15. Shift from chemotherapy to targeted agents
16. Clinically established molecular targets
17. Targeted therapy: proteins
18. Targeted therapy: small molecules
19. Changes brought about by targeting: Efficacy
20. Changes brought about by targeting: Toxicity
21. Biomarkers in drug development (1)
22. What is currently known (Biomarkers)
23. What research is ongoing (Biomarkers)?
24. Example for the use of biomarkers
25. What is currently known (Angiogenesis)?
26. The VEGF family and its receptors
27. VEGF targeted therapy
28. Phase 3 trial of bevacizumab in MCRC: Survival
29. Biological correlates of bevacizumab
30. Does toxicity correlate with response?
31. Metastatic CRC
32. What research is ongoing (Agents)?
33. Sorafenib
34. Phase I of sorafenib (DF/HCC, USC)
35. Phase I's of sorafenib (pooled)
36. Does toxicity correlate with time to progression?
37. Phase III trial RCC
38. Future directions in cancer treatment options
39. Sequencing: same pathways, different mutations
40. Core pathways altered in pancreatic cancer
41. Core pathways altered in colorectal cancer
42. Implications of genetic sequencing of solid tumors
43. Pancreatic cancers sequencing
44. Epigenetics and cancer therapy
45. Conclusions
46. Closing remarks

Topics Covered

• Why pursuing new therapeutic approaches in cancer is important
• Prevention and screening
• Current cancer therapy: non-surgical
• Most chemotherapy targets DNA
• Chemotherapy effects
• Current state of cancer therapy: efficacy and toxicity
• Molecular pathogenesis of cancer
• Pursuing targeted therapy in cancers
• Targeted biologic therapies
• Evolving targets and agents
• Shift from chemotherapy to targeted agents
• Clinically established molecular targets in malignancies
• Targeted therapy: proteins and small molecules
• Changes brought about by targeting: efficacy and toxicity
• Biomarkers in drug development
• What is currently known: angiogenesis
• The VEGF family and its receptors
• Bevacizumab and Sorafenib
• Does toxicity correlate with response?
• What research is ongoing: agents?
• Future directions in cancer treatment options
• Core pathways altered in pancreatic and colorectal cancer
• Implications of genetic sequencing of solid tumors to date
• Epigenetics and cancer therapy

Links

Series:

• Cancer Therapy

Categories:

• Cancer
• Clinical Practice

Therapeutic Areas:

• Oncology

Talk Citation

Publication History

• Published on January 6, 2009
• Archived on February 25, 2021

Financial Disclosures

• Dr. Jeffrey Clark has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.